Medications for Cryopyrinassociated Periodic Syndromes
3 results
Arcalyst (rilonacept)
(rilonacept)Kiniksa Pharmaceuticals (UK), Ltd.
Usage: ARCALYST (rilonacept) is indicated for treating Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in patients 12 years and older; maintenance of remission in Deficiency of IL-1 Receptor Antagonist (DIRA); and recurrent pericarditis in patients 12 years and older.
Ilaris (canakinumab)
(canakinumab)Novartis Pharmaceuticals Corporation
Usage: ILARIS (canakinumab) is indicated for treating autoinflammatory periodic fever syndromes, including CAPS, TRAPS, HIDS, and FMF, as well as active Still’s Disease (AOSD and SJIA). It is also used for symptomatic relief of gout flares in adults unable to use NSAIDs or colchicine.
Kineret (anakinra)
(anakinra)Swedish Orphan Biovitrum AB (publ)
Usage: KINERET is indicated for treating moderately to severely active rheumatoid arthritis in adults who have not responded to DMARDs, as well as for Neonatal-Onset Multisystem Inflammatory Disease (NOMID) and Deficiency of Interleukin-1 Receptor Antagonist (DIRA). It can be used alone or with non-TNF blocking DMARDs.